Clinical and experimental studies of cancer. We are running a randomized clinical trial on local treatment of breast cancer liver metastases and participate in several trials in national and international collaborations. In our lab, we study the MAPK signaling pathway and develop a model i C. elegans to identify novel treatments of cancer.
Our group has funding from:
We are running the multicenter randomized clinical trial BRECLIM to study if local treatment should be offered to patients suffering from breast cancer liver metatsases. Read more here.
We participate in the EPIC-network to study hepatocellular cancer and melanoma. We also participate in the international snapshot study of outcomes after liver surgery and in studies within the national registry on cancer in the liver and the bile ducts
Cancer progression is often driven by oncogenic mutations in the MAPK signalling pathway. Our group studies BRAF- and KRAS-activated cancer to explore targets to circumvent drug resistance and to find novel treatments. Currently, we focus on the tumour suppressor LRIG1 in relation to BRAF inhibitor resistance in malignant melanoma. We take advantage of the biobanks in Umeå in order to confirm results from in vitro cell culture studies in a patient material. Our group has experience from the model organism C. elegans and we recently equipped our lab for nematode research. We develop the C. elegans in vivo model to explore novel targets to block MAPK-driven cancer. https://www.umu.se/en/wallenberg-centre-for-molecular-medicine/research/wcmm-associerade-forskare/oskar-hemmingsson/
In a second project we test a novel concept of surface microdialysis to evaluate perioperative liver metabolism.